BIVI insider transaction filings

BIOVIE INC. — 25 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-28. Screen BIVI transaction legs live →

Insider transaction summary — last 90 days

2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
DO CUONG V — President & CEO, Director11 leg · 15,210 sh · $31,637
Palumbo Joseph M — Chief Medical Officer11 leg · 4,843 sh · $10,461
KIM JOANNE WENDY — Chief Financial Officer11 leg · 2,500 sh · $5,450
Chappell Amy Suzon — Director11 leg · 727 sh · $1,570

Recent Form 4 filings — BIOVIE INC.

FiledFormInsiderReported transactionsSource
2026-08-284Palumbo Joseph M — Chief Medical OfficerPurchase (P): 4,843 @ $2.16EDGAR
2026-08-284KIM JOANNE WENDY — Chief Financial OfficerPurchase (P): 2,500 @ $2.18EDGAR
2026-08-284Chappell Amy Suzon — DirectorPurchase (P): 727 @ $2.16EDGAR
2026-08-284DO CUONG V — President & CEO, DirectorPurchase (P): 15,210 @ $2.08EDGAR
2026-01-094Palumbo Joseph M — Chief Medical OfficerGrant/award (A): 132,000 (derivative) @ $0EDGAR
2026-01-094KIM JOANNE WENDY — Chief Financial OfficerGrant/award (A): 110,100 (derivative) @ $0EDGAR
2026-01-094Sherman Michael Edward — DirectorGrant/award (A): 80,000 (derivative) @ $0 · Grant/award (A): 341,100 (derivative) @ $0EDGAR
2026-01-094Farag Kameel D. — DirectorGrant/award (A): 57,500 (derivative) @ $0EDGAR
2026-01-094Chappell Amy Suzon — DirectorGrant/award (A): 57,500 (derivative) @ $0EDGAR
2026-01-094Lang James Paul — DirectorGrant/award (A): 90,000 (derivative) @ $0 · Grant/award (A): 330,500 (derivative) @ $0EDGAR
2026-01-094DO CUONG V — President & CEO, DirectorGrant/award (A): 665,300 (derivative) @ $0EDGAR
2026-01-094ROGICH SIGMUND — DirectorGrant/award (A): 70,000 (derivative) @ $0 · Grant/award (A): 141,100 (derivative) @ $0EDGAR
2025-08-134DO CUONG V — President & CEO, DirectorPurchase (P): 5,000 · Purchase (P): 5,000 (derivative)EDGAR
2025-01-074Sherman Michael Edward — DirectorGrant/award (A): 56,900 (derivative) @ $0 · Grant/award (A): 23,325 (derivative) @ $0EDGAR
2025-01-074Lang James Paul — DirectorGrant/award (A): 61,600 (derivative) @ $0 · Grant/award (A): 22,690 (derivative) @ $0EDGAR
2025-01-074Palumbo Joseph M — Chief Medical OfficerGrant/award (A): 15,417 (derivative) @ $0EDGAR
2025-01-074KIM JOANNE WENDY — Chief Financial OfficerGrant/award (A): 14,417 (derivative) @ $0EDGAR
2025-01-074DO CUONG V — President & CEO, DirectorGrant/award (A): 104,502 (derivative) @ $0EDGAR
2025-01-074Hariri Robert J — DirectorGrant/award (A): 49,800 (derivative) @ $0 · Grant/award (A): 21,815 (derivative) @ $0EDGAR
2025-01-074ROGICH SIGMUND — DirectorGrant/award (A): 32,700 @ $0 · Grant/award (A): 22,070 (derivative) @ $0EDGAR
2025-01-074BERMAN RICHARD J — DirectorGrant/award (A): 34,200 @ $0 · Grant/award (A): 23,155 (derivative) @ $0EDGAR
2024-07-124Palumbo Joseph M — Chief Medical OfficerTax withholding (F): 2,476 @ $5.51 · Tax withholding (F): 2,476 @ $1.18 · Grant/award (A): 116,000 @ $0 · Tax withholding (F): 29,000 @ $0.47 · Grant/award (A): 156,000 (derivative) @ $0EDGAR
2024-07-124KIM JOANNE WENDY — Chief Financial OfficerTax withholding (F): 2,476 @ $5.51 · Tax withholding (F): 2,476 @ $1.18 · Grant/award (A): 73,000 @ $0 · Tax withholding (F): 18,250 @ $0.47 · Grant/award (A): 99,000 (derivative) @ $0EDGAR
2024-07-124DO CUONG V — President & CEO, DirectorTax withholding (F): 4,953 @ $5.51 · Tax withholding (F): 4,953 @ $1.18 · Grant/award (A): 168,000 @ $0 · Tax withholding (F): 42,000 @ $0.47 · Grant/award (A): 227,000 (derivative) @ $0EDGAR
2024-03-064DO CUONG V — President & CEO, DirectorPurchase (P): 10,000 · Purchase (P): 5,000 (derivative)EDGAR

Recent 8-K events — BIOVIE INC.

FiledFormItems reportedSource
2026-09-148-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-138-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-128-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2025-08-118-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-07-238-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-06-278-K3.03 — Material Modification to Rights of Security HoldersEDGAR
2025-06-248-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2025-03-288-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2024-11-088-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=BIVI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →